Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | USP8 | P40818 | 1/20 | 1.00 |
| ▸ | USP5 | P45974 | 1/20 | 1.00 |
| ▸ | USP4 | Q13107 | 1/20 | 1.00 |
| ▸ | USP7 | Q93009 | 1/20 | 1.00 |
| ▸ | MYC | P01106 | 9/20 | 0.36 |
| ▸ | WDR5 | P61964 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13065926 | 0.92 | USP2 (0.84) | USP2USP8USP5USP4USP7 | |
| SCHEMBL13985248 | 0.86 | USP2 (0.74) | USP2USP8USP5USP4USP7 | |
| SCHEMBL10412909 | 0.75 | USP2 (0.60) | USP2USP8USP5USP4USP7 | |
| SCHEMBL11173991 | 0.72 | USP2 (0.56) | USP2USP8USP5USP4USP7 | |
| SCHEMBL9387702 | 0.70 | USP2 (0.53) | USP2USP8USP5USP4USP7 | |
| SCHEMBL10413718 | 0.67 | USP2 (0.50) | USP2USP8USP5USP4USP7 | |
| SCHEMBL11374071 | 0.64 | USP2 (0.47) | USP2USP8USP5USP4USP7 | |
| SCHEMBL11373307 | 0.64 | USP2 (0.47) | USP2USP8USP5USP4USP7 | |
| SCHEMBL11367939 | 0.64 | USP2 (0.47) | USP2USP8USP5USP4USP7 | |
| SCHEMBL11373902 | 0.64 | USP2 (0.47) | USP2USP8USP5USP4USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031467-A | Application of deubiquitinase inhibitor and OTUD7A-HINT1-mTOR axis in central nervous system regeneration | 中国科学院动物研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-115427076-B | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118979088-A | Method for screening ubiquitination modified target protein in chicken primordial germ cell generation process | 扬州大学 | 2024-11-19 | — | — | CN | claimed |
| CN-118978584-A | Method for enriching ubiquitin and enrichment kit | 辉源生物科技（上海）有限公司 | 2024-11-19 | — | — | CN | claimed |
| US-20240245664-A1 | METHODS OF USING USP15 INHIBITORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2024-07-25 | — | — | US | claimed |
| CN-117860894-A | Application of USP5 inhibitor in preparation of antiviral drugs | 苏州系统医学研究所 | 2024-04-12 | — | — | CN | claimed |
| CN-111650327-B | Method for searching differential expression protein between different cells or tissues of Rugao yellow chicken based on non-calibrated proteomics technology | 扬州大学 | 2023-06-02 | — | — | CN | claimed |
| US-20230087388-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | IMMUNOLOGIK GMBH (DE) | 2023-03-23 | — | — | US | claimed |
| WO-2023039405-A1 | METHODS OF USING USP15 INHIBITORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2023-03-16 | — | — | WO | claimed |
| EP-4110393-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | Immunologik GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| CN-115427076-A | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2022-12-02 | — | — | CN | claimed |
| CN-112933090-B | Application of deubiquitinase inhibitor in preparation of anti-rabies virus medicine | 军事科学院军事医学研究院军事兽医研究所 | 2022-11-08 | — | — | CN | claimed |
| EP-3302522-B1 | MEANS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD). | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-08-31 | — | — | EP | claimed |
| EP-4011367-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| US-20220111019-A1 | BRCA1 MODULATING COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-04-14 | — | — | US | claimed |
| EP-3166604-B1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2020-11-18 | — | — | EP | claimed |
| US-10588896-B2 | Agents for the treatment of retroviral infectious diseases | IMMUNOLOGIK GMBH (DE) | 2020-03-17 | — | — | US | claimed |
| US-20170202814-A1 | AGENTS FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2017-07-20 | — | — | US | claimed |
| EP-3166604-A1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | Immunologik GmbH (DE) | 2017-05-17 | — | — | EP | claimed |
| WO-2016004917-A1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2016-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087388-A1 | INHIBITORS OF HUMAN DEUBIQUITINASES FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | USP47, USP7, USP1 | USP2 7/4885USP8 6/4885USP5 10/4885 |
| US-20170202814-A1 | AGENTS FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | USP3, USP28, USP5 | USP2 10/4885USP8 15/4885USP5 3/4885 |
| US-10588896-B2 | Agents for the treatment of retroviral infectious diseases | USP3, USP28, USP5 | USP2 10/4885USP8 15/4885USP5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.